benzoyl peroxide/tretinoin (IDP-120) / Bausch Health - LARVOL DELTA

Real-World Adverse Events Associated with Encapsulated Benzoyl Peroxide/Tretinoin, 3%/0.1%, and Encapsulated Benzoyl Peroxide, 5. (PubMed, Dermatol Ther (Heidelb)) - "The adverse events were generally mild and restricted to local irritation, pruritus, burning sensation, and erythema. The real-world incidence and type of adverse events reported by the community for encapsulated benzoyl peroxide/tretinoin, 3%/0.1%, and benzoyl peroxide, 5%, were consistent with the safety and tolerability findings from the phase III clinical studies of these treatments."

Adverse events • Journal • Real-world • Real-world evidence • Acne Vulgaris • Dermatology • Pruritus • Rosacea

Results of Two Phase 1 Studies of Encapsulated Benzoyl Peroxide/Tretinoin, 3%/0.1%: An Evaluation of the Phototoxic and Photoallergic Potential (WCD 2023) - "In both studies, there was no evidence of phototoxicity or photoallergy for E-BPO/T or vehicle"

P1 data • Acne Vulgaris • Dermatology • Immunology • Pediatrics

Results From Two Phase 1 Skin Irritation and Sensitization Safety Studies of Encapsulated Benzoyl Peroxide/Tretinoin, 3%/0.1% (WCD 2023) - "Microencapsulation results in a slower release of active drug to the skin after application, which likely contributes to the improved tolerability of E-BPO/T. Under exaggerated conditions of the studies, E-BPO/T was considered moderately irritating, whereas the vehicle was considered not irritating. No subjects discontinued the study due to irritation, and there were no reported adverse events."

Clinical • P1 data • Acne Vulgaris • Dermatology

Efficacy and Safety of Microencapsulated Benzoyl Peroxide and Microencapsulated Tretinoin for the Treatment of Acne Vulgaris: Results from Two Phase 3 Double-Blind, Randomized, Vehicle-Controlled Studies. (PubMed, J Am Acad Dermatol) - "E-BPO/T provided statistically significant and clinically relevant improvements in IGA and inflammatory and noninflammatory lesion counts and was well tolerated in subjects with moderate to severe acne."

Journal • P3 data • Acne Vulgaris • Dermatology

Impact of Topical Vehicles and Cutaneous Delivery Technologies on Patient Adherence and Treatment Outcomes in Acne and Rosacea. (PubMed, J Clin Aesthet Dermatol) - "Further research is needed to fully highlight the impact of patient satisfaction and modern topical formulations on adherence and treatment outcomes. Drug microencapsulation is a delivery technology that has enabled development of a topical fixed-dose combination of benzoyl peroxide and tretinoin preventing the oxidation of tretinoin by benzoyl peroxide and improving the tolerability of the active ingredients."

Adherence • Journal • Review • Acne Vulgaris • Dermatology • Rosacea

An Evaluation of the Phototoxic and Photoallergic Potential of Microencapsulated Benzoyl Peroxide and Tretinoin (AAD 2023) - "In both studies, there was no evidence of phototoxicity or photoallergy for E-BPO/T or vehicle."

Acne Vulgaris • Dermatology • Immunology

Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris. (PubMed, Ann Pharmacother) - "A systematic review of the literature was performed using the terms Twyneo OR tretinoin and benzoyl peroxide OR S6G5T-3 in MEDLINE (PubMed) and EMBASE. Tretinoin 0.1%-benzoyl peroxide 3% cream is safe and effective for the treatment of moderate-to-severe acne. Long-term trial data on efficacy and tolerability are not yet available."

Clinical • Journal • Review • Acne Vulgaris • Dermatology • Pain

Review of Tretinoin-Benzoyl Peroxide in The Treatment of Acne Vulgaris. (PubMed, J Drugs Dermatol) - "Tret-BPO is a safe and effective novel therapy for acne vulgaris. Poor adherence is a major hurdle in management; the combination of two separate first-line drugs may address this hurdle by decreasing the complexity of treatment regimens. J Drugs Dermatol. 2022;21(10):1098-1103. doi:10.36849/JDD.6808."

Journal • Review • Acne Vulgaris • Dermatology

Enhancing Topical Pharmacotherapy for Acne and Rosacea: Vehicle Choices and Outcomes. (PubMed, J Clin Aesthet Dermatol) - "One of the latest vehicle technologies in acne and rosacea to enhance efficacy, stability, and tolerability is microencapsulation of benzoyl peroxide and tretinoin, which resulted in significant efficacy and good tolerability in patients with each of these two diseases. Other new vehicle technologies include a polymeric form of tretinoin and a microsphere product that combines tretinoin plus clindamycin...This review summarizes drug delivery systems that have been developed with the aim of improving outcomes for patients being treated for either acne or rosacea. It also focuses, where possible, on formulations that have been evaluated in clinical studies."

Journal • Review • Acne Vulgaris • Dermatology • Rosacea

Tretinoin/benzoyl peroxide cream (Twyneo) for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

Topical dapsone in the treatment of acne: a systematic review. (PubMed, Int J Dermatol) - "Dapsone gel offers a safe and promising alternative therapy for patients with difficult to treat acne or those who experience adverse effects to first-line therapies."

Journal • Review • Acne Vulgaris • Dermatology

Guidance for the pharmacological management of acne vulgaris. (PubMed, Expert Opin Pharmacother) - "Acne is not a traditional infectious disease and so while antibiotics may improve symptoms, they do not reliably resolve the condition. Thus, there is currently a tendency to opt for antibiotic-sparing treatment strategies whenever possible."

Journal • Acne Vulgaris • Dermatology • Infectious Disease

[VIRTUAL] Meclozine, a novel anti-inflammatory therapeutic in C. acnes-induced inflammation in vitro and in vivo (AAD-VMX 2021) - "When comparing the effect of meclozine with common commercial molecules (6 µM) used in acne treatment (erythromycine, clindamycine, benzoyl peroxide, isotretinoine, adapalene and retinoic acid) only adapalene shown comparable CXCL8 inhibition to meclozine but was associated with strong cytotoxicity. Meclozine-gel application reduced dose-dependently inflammation in a in vivo C. acnes-induced ear inflammation model in mice by 19% (p=0.04), 13% (p=0.14), 26% (p=0.01), 48% (p=0.002), and 56% (p=8.2 10-5) at 0.1, 0.5, 1, 2 and 4% concentrations, respectively. Therefore, meclozine appears to be a promising molecular compound to be tested clinically."

Preclinical • Acne Vulgaris • Immunology • Inflammation • CXCL8 • GLI2

Microencapsulated Benzoyl Peroxide and Tretinoin for the Treatment of Acne Vulgaris: Results from a Phase 2 Multicenter, Double-Blind, Randomized, Vehicle-Controlled Study. (PubMed, Skinmed) - "All treatments were safe with comparable skin tolerability. The significant superiority of both combinations over VC and numerical superiority over E-BP and E-ATRA were achieved without an increase in adverse events or reduced skin tolerability."

Clinical • Journal • P2 data • Acne Vulgaris • Dermatology